BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND NOTCH1, TAN1, P46531, 4851, ENSG00000148400, hN1 AND Clinical Outcome
12 results:

  • 1. Blastoid and Pleomorphic Mantle Cell lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features.
    Khanlari M; Mo H; Kim DH; Sakhdari A; Young KH; Jain P; Wang M; Li S; Kanagal-Shamanna R; Miranda RN; Vega F; Medeiros LJ; Ok CY
    Am J Surg Pathol; 2023 Aug; 47(8):849-858. PubMed ID: 37288826
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. SIRT1 regulates the phosphorylation and degradation of P27 by deacetylating CDK2 to promote T-cell acute lymphoblastic leukemia progression.
    Wang F; Li Z; Zhou J; Wang G; Zhang W; Xu J; Liang A
    J Exp Clin Cancer Res; 2021 Aug; 40(1):259. PubMed ID: 34407842
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. CARMA1 is required for notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.
    Zhang N; Xu J; Wang R; Pan T; Zhang H; Yin L; Yao Y; Xu L; Zhu S; Wu Q; Li Z; Liu X; Xu K; Niu M
    J Mol Med (Berl); 2021 Oct; 99(10):1447-1458. PubMed ID: 34223928
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group.
    Weinberg OK; Chisholm KM; Ok CY; Fedoriw Y; Grzywacz B; Kurzer JH; Mason EF; Moser KA; Bhattacharya S; Xu M; Babu D; Foucar K; Tam W; Bagg A; Orazi A; George TI; Wang W; Wang SA; Arber DA; Hasserjian RP
    Mod Pathol; 2021 Jul; 34(7):1358-1366. PubMed ID: 33526873
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Biclonal lymphoproliferative disorders: another association with notch1-mutated chronic lymphocytic leukaemias.
    Fogarty H; Dowling A; O'Brien D; Langabeer S; Bacon CL; Flavin R; O'Dwyer M; Hennessy B; O'Leary H; Crotty G; Henderson R; Nolan J; Thornton P; Vandenberghe E; Quinn F
    Ir J Med Sci; 2021 Aug; 190(3):1087-1094. PubMed ID: 33068240
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Clonal heterogeneity and its prognostic significance in acute lymphoblastic leukemia].
    Lyu XD; Guo Z; Li YW; Hu JY; Fan RH; Song YP
    Zhonghua Nei Ke Za Zhi; 2020 Aug; 59(8):629-633. PubMed ID: 34865381
    [No Abstract]    [Full Text] [Related]  

  • 7. Significance of notch1 mutations détections in T-acute lymphoblastic leukemia patients.
    Aref S; El Agdar M; Salama O; Zeid TA; Sabry M
    Cancer Biomark; 2020; 27(2):157-162. PubMed ID: 31796666
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Mutation of IL-7R in Adult Patients with T-cell Acute Lymphoblastic Leukemia and Its clinical Significance].
    Xiao LC; Li M; Ge Z; Gu Y; Zhou XL; Guo X; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1014-8. PubMed ID: 27531766
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Targeting notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
    Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
    Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. notch1 and FBXW7 mutations favor better outcome in pediatric South Indian T-cell acute lymphoblastic leukemia.
    Natarajan V; Bandapalli OR; Rajkumar T; Sagar TG; Karunakaran N
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e23-30. PubMed ID: 25493453
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
    Arcaini L; Rossi D; Lucioni M; Nicola M; Bruscaggin A; Fiaccadori V; Riboni R; Ramponi A; Ferretti VV; Cresta S; Casaluci GM; Bonfichi M; Gotti M; Merli M; Maffi A; Arra M; Varettoni M; Rattotti S; Morello L; Guerrera ML; Sciarra R; Gaidano G; Cazzola M; Paulli M
    Haematologica; 2015 Feb; 100(2):246-52. PubMed ID: 25381127
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
    Neumann M; Coskun E; Fransecky L; Mochmann LH; Bartram I; Sartangi NF; Heesch S; Gökbuget N; Schwartz S; Brandts C; Schlee C; Haas R; Dührsen U; Griesshammer M; Döhner H; Ehninger G; Burmeister T; Blau O; Thiel E; Hoelzer D; Hofmann WK; Baldus CD
    PLoS One; 2013; 8(1):e53190. PubMed ID: 23359050
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.